Logo image of CGEN

COMPUGEN LTD (CGEN) Stock Fundamental Analysis

USA - NASDAQ:CGEN - IL0010852080 - Common Stock

1.34 USD
-0.06 (-4.29%)
Last: 9/12/2025, 8:00:00 PM
1.39 USD
+0.05 (+3.73%)
After Hours: 9/12/2025, 8:00:00 PM
Fundamental Rating

3

CGEN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. While CGEN seems to be doing ok healthwise, there are quite some concerns on its profitability. CGEN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CGEN had negative earnings in the past year.
CGEN had a negative operating cash flow in the past year.
In the past 5 years CGEN always reported negative net income.
CGEN had negative operating cash flow in 4 of the past 5 years.
CGEN Yearly Net Income VS EBIT VS OCF VS FCFCGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.18%, CGEN is in the better half of the industry, outperforming 78.74% of the companies in the same industry.
With a decent Return On Equity value of -38.53%, CGEN is doing good in the industry, outperforming 72.09% of the companies in the same industry.
Industry RankSector Rank
ROA -18.18%
ROE -38.53%
ROIC N/A
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
CGEN Yearly ROA, ROE, ROICCGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CGEN has a better Gross Margin (62.33%) than 78.56% of its industry peers.
CGEN's Gross Margin has declined in the last couple of years.
CGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
CGEN Yearly Profit, Operating, Gross MarginsCGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
Compared to 5 years ago, CGEN has more shares outstanding
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEN Yearly Shares OutstandingCGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CGEN Yearly Total Debt VS Total AssetsCGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CGEN has an Altman-Z score of -4.76. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.76, CGEN perfoms like the industry average, outperforming 40.48% of the companies in the same industry.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.76
ROIC/WACCN/A
WACC8.82%
CGEN Yearly LT Debt VS Equity VS FCFCGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.74 indicates that CGEN has no problem at all paying its short term obligations.
CGEN has a Current ratio (4.74) which is comparable to the rest of the industry.
CGEN has a Quick Ratio of 4.74. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CGEN (4.74) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.74
Quick Ratio 4.74
CGEN Yearly Current Assets VS Current LiabilitesCGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for CGEN have decreased strongly by -120.00% in the last year.
CGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -48.16%.
The Revenue has been growing by 66.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-120%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-48.16%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-81.24%

3.2 Future

The Earnings Per Share is expected to decrease by -18.07% on average over the next years. This is quite bad
The Revenue is expected to decrease by -1.00% on average over the next years.
EPS Next Y-114.63%
EPS Next 2Y-27.92%
EPS Next 3Y-9.03%
EPS Next 5Y-18.07%
Revenue Next Year-84.47%
Revenue Next 2Y-36.53%
Revenue Next 3Y-11.31%
Revenue Next 5Y-1%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CGEN Yearly Revenue VS EstimatesCGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
CGEN Yearly EPS VS EstimatesCGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEN Price Earnings VS Forward Price EarningsCGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEN Per share dataCGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A cheap valuation may be justified as CGEN's earnings are expected to decrease with -9.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.92%
EPS Next 3Y-9.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPUGEN LTD

NASDAQ:CGEN (9/12/2025, 8:00:00 PM)

After market: 1.39 +0.05 (+3.73%)

1.34

-0.06 (-4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners17.39%
Inst Owner Change0.19%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap125.34M
Analysts88
Price Target7.14 (432.84%)
Short Float %0.99%
Short Ratio4.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.63%
Min EPS beat(2)-42.6%
Max EPS beat(2)-20.66%
EPS beat(4)0
Avg EPS beat(4)-86.89%
Min EPS beat(4)-193.59%
Max EPS beat(4)-20.66%
EPS beat(8)1
Avg EPS beat(8)-75.17%
EPS beat(12)4
Avg EPS beat(12)-42.88%
EPS beat(16)8
Avg EPS beat(16)-26.17%
Revenue beat(2)0
Avg Revenue beat(2)-54.18%
Min Revenue beat(2)-68.82%
Max Revenue beat(2)-39.54%
Revenue beat(4)0
Avg Revenue beat(4)-51.51%
Min Revenue beat(4)-91.73%
Max Revenue beat(4)-5.97%
Revenue beat(8)2
Avg Revenue beat(8)-17.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.67%
PT rev (3m)47.37%
EPS NQ rev (1m)-33.34%
EPS NQ rev (3m)-44.45%
EPS NY rev (1m)-22.43%
EPS NY rev (3m)-188.57%
Revenue NQ rev (1m)-64.17%
Revenue NQ rev (3m)-70.61%
Revenue NY rev (1m)-53.74%
Revenue NY rev (3m)-77.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.66
P/FCF N/A
P/OCF N/A
P/B 2.49
P/tB 2.49
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.24
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.18%
ROE -38.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.33%
FCFM N/A
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.39%
Cap/Sales 1.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.74
Quick Ratio 4.74
Altman-Z -4.76
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)54.17%
Cap/Depr(5y)49.83%
Cap/Sales(3y)2.49%
Cap/Sales(5y)4.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-120%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-114.63%
EPS Next 2Y-27.92%
EPS Next 3Y-9.03%
EPS Next 5Y-18.07%
Revenue 1Y (TTM)-48.16%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-81.24%
Revenue Next Year-84.47%
Revenue Next 2Y-36.53%
Revenue Next 3Y-11.31%
Revenue Next 5Y-1%
EBIT growth 1Y-335.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.3%
OCF growth 3YN/A
OCF growth 5YN/A